Drug Shortage Updates from ASHP

Some recent updates from the American Society of Health-Systems Pharmacists of interest to people with colon and rectal cancer: Fluorouracil (5-FU) as of 8/31/11: On back order from Teva, APP Pharmaceuticals, and Mylan Institutional.  Manufacturing delays at Teva appear to have caused increased demand from other companies. Leucovorin as of 8/31/11:   Bedford has some powderized…  Read More

5-FU Added to Drug Shortage List

This morning the FDA added fluorouracil to its drug shortage list. The American Society of Healthcare Pharmacists (ASHP) has also reported a shortage of fluorouracil (5-FU), a common backbone drug for colorectal cancer chemotherapy. Two manufacturers have some doses of the drug on intermittent back order and are shipping it as it becomes available.  A third…  Read More

Leucovorin Shortage Update: Imported Supplies Available

The FDA issued a shortage update for leucovorin on July 21, 2011. While leucovorin remains in shortage from all three US manufacturers, the FDA is temporarily allowing Teva Pharmaceuticals to import calcium folinate solution for injection from Europe. The imported solution is the same strength as  powdered leucovorin calcium for injection once water is added to…  Read More

Growing Drug Shortages Cost Money, Put Patients at Risk

Shortages of prescription drugs cost the United States more than $200 million. In addition, shortages force doctors to delay or cancel treatment.  Patient safety is compromised when doctors have to use different or unfamiliar drugs when they can’t get the right ones. In the six months from July to December of 2010, 240 drugs were either…  Read More

Leucovorin Update: Teva Pushes Back Release to April 2011

Latest information from the FDA says that manufacturing delays will prevent shipments of leucovorin from Teva Pharmaceuticals until next April. Teva has leucovorin calcium lyophilized powder 100 mg and 350 mg vials on back order and the company does not anticipate release until April 2011. Bedford Laboratories also cites manufacturing delays but is “releasing product as…  Read More